As reported in Rediff business, Daiichi has reorganized its R&D effort into 4 main hubs - including a new site in India resulting from its acquisition of Ranbaxy. Daiichi currently owns 63% of Ranbaxy but 100% of the newly formed R&D group called Research Center in India (RCI) that consists of 170 researchers.
RCI will focus on inflammatory and infectious disease research. Daiichi has transfer a half dozen early discovery programs from Japan to India. The RCI mandate is to identify potential drug candidates that will then be transferred back to Japan for further development.
Daiichi also has R&D hubs in Japan, the US at Asubio Pharma, and in Germany at U3 Pharma.